- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06152029
Temporary Peripheral Nerve Stimulation System for Osteoarthritis of the Knee
November 21, 2023 updated by: Mansoor Aman, MD
Efficacy of a Temporary Peripheral Nerve Stimulation System in Patients With Osteoarthritis of the Knee
The purpose of this study is to demonstrate the treatment outcomes of patients with chronic knee pain secondary to osteoarthritis that have received a temporary peripheral nerve stimulation system.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Merve Buluk Figueira, MS
- Phone Number: 9204561551
- Email: merve.figueira@aah.org
Study Contact Backup
- Name: Mansoor M Aman, MD
- Phone Number: 9204567715
- Email: mansoor.aman@aah.org
Study Locations
-
-
Wisconsin
-
Fond Du Lac, Wisconsin, United States, 54937
- Recruiting
- Aurora Health Center
-
Contact:
- Merve Buluk Figueira, MS
- Phone Number: 920-456-1551
- Email: merve.figueira@aah.org
-
Sub-Investigator:
- Lauren Littlefield, MD
-
Oshkosh, Wisconsin, United States, 54914
- Recruiting
- Aurora Health Oshkosh
-
Principal Investigator:
- Mansoor Aman, MD
-
Sub-Investigator:
- Vishal Patel, MD
-
Contact:
- Merve Buluk Figueira, MS
- Phone Number: 920-456-1551
- Email: merve.figueira@aah.org
-
Sub-Investigator:
- Lauren Littlefield, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Study population includes patients with chronic knee pain secondary to osteoarthritis of the knee and will receive a temporary peripheral nerve stimulation device.
Description
Inclusion Criteria:
- Age of 21 and older
- Will receive a temporary PNS system for the management of chronic knee pain secondary to osteoarthritis
- Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English
- Be willing and capable of giving informed consent
- Be willing and able to comply with study-related requirements, procedures, and scheduled visits
Exclusion Criteria:
- No knee pain at rest
- Same nerve targeted for both Radiofrequency Ablation (RFA) and Peripheral Nerve Stimulation (PNS) in less than 6 months post RFA, if applicable
- Pregnancy
- History of repetitive skin infections
- Vulnerable populations (e.g., prisoners, minors, students, employees)
- Any other condition that may interfere with the ability to participate in a clinical trial (e.g., anatomy that may interfere with lead placement, nerve damage, compromised immune system, uncontrolled diabetes)
- Confounding conditions such as lumbar radiculopathy
- Deep brain stimulation system, implanted active cardiac implant (e.g. pacemaker of defibrillator), or any other implantable neuro-stimulator whose stimulus current pathway may overlap the SPRINT system.
- Be involved in an injury claim under current litigation
- Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain
- Have a pending or approved worker's compensation claim
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients treated with a temporary PNS system
These patients will receive a temporary PNS system for their knee pain secondary to osteoarthritis
|
This system remains in place up to 60 days, then removed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average change from baseline to end of treatment in average pain intensity measured through BPI-SF item 5.
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average change from baseline to end of treatment in health-related quality of life measured through PROMIS-29.
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Average change from baseline to end of treatment in pain interference measured through BPI-SF.
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Average change in chronic pain related medication intake at end of treatment compared to baseline in Morphine Miligram Equivalents (MME)
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Overall patient global impression of change (PGIC) at end of treatment.
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Overall incidence of lead migration/fracture at the end of treatment.
Time Frame: up to 60 days post lead placement
|
up to 60 days post lead placement
|
Average change from baseline to 7- and 30-days post-implant; and 6- and 12-months post-explant in average pain intensity measured through BPI-SF item 5.
Time Frame: 7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
Average change from baseline to 6- and 12-months post-explant in health-related quality of life measured through PROMIS-29.
Time Frame: 7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
Average change from baseline to 6- and 12-months post-explant in pain interference measured through BPI-SF.
Time Frame: 7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
7 and 30 days post lead placement; and 6 and 12 month post lead pull
|
Overall patient global impression of change (PGIC) at 6 months and end of study.
Time Frame: 6 and 12 months post lead pull
|
6 and 12 months post lead pull
|
Overall incidence of lead migration/fracture during the study.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mansoor M Aman, MD, Director, Interventional Pain Medicine- Oshkosh & Fond du Lac Department of Anesthesiology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2023
Primary Completion (Estimated)
June 15, 2024
Study Completion (Estimated)
June 15, 2025
Study Registration Dates
First Submitted
November 15, 2023
First Submitted That Met QC Criteria
November 21, 2023
First Posted (Actual)
November 30, 2023
Study Record Updates
Last Update Posted (Actual)
November 30, 2023
Last Update Submitted That Met QC Criteria
November 21, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-832
- 23.135E (Other Identifier: Aurora IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Temporary PNS system
-
Nalu Medical, Inc.RecruitingChronic Pain | Peripheral NeuralgiaUnited States
-
Nalu Medical, Inc.RecruitingChronic Pain | Peripheral Neuropathy | Peripheral NeuralgiaUnited States
-
SPR Therapeutics, Inc.CompletedPain | Postoperative Pain | Orthopedic Disorder | Total Knee Arthroplasty | Total Knee ReplacementUnited States
-
Epineuron Technologies Inc.RecruitingNerve InjuryCanada, United States
-
SPR Therapeutics, Inc.RecruitingCervicogenic Headache | Occipital NeuralgiaUnited States
-
SPR Therapeutics, Inc.United States Department of DefenseActive, not recruitingPostoperative Pain | Total Knee Arthroplasty | Total Knee Replacement | Partial Knee ReplacementUnited States
-
University of Sao Paulo General HospitalFundação Faculdade de MedicinaCompleted
-
SPR Therapeutics, Inc.TerminatedAmputation | Neuropathic PainUnited States
-
ReFlow Medical, Inc.RecruitingPeripheral Arterial Disease | Critical Limb IschemiaUnited States